Biocampus

  • Schrift vergrößern
  • Standard-Schriftgröße
  • Schriftgröße verkleinern

Axiogenesis Member of Ncardia Group

E-Mail Drucken PDF

About Ncardia

Ncardia (www.ncardia.com) believes that stem cell technology will help to get better medicines to patients faster. The company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC-derived cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®) as well cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the CardioplateTM product line of quality controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS.4U®, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®.

Ncardia is committed to deliver its clients working assays solutions through in house assay development and extensive support. The company has a wide range of supported applications and compound assay services such as of electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology and toxicology testing. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening. 

Ncardia is based in Belgium, The Netherlands, Germany and in the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.

 

Axiogenesis AG Ncardia Logo

Member of the Ncardia Group

Building S20  Nattermannallee 1

50829 Köln

phone: +49 221 99 88 18-0

fax:      +49 2 21 99 88 18-10

mail:    info@ncardia.com

web:    www.ncardia.com